ST. LOUIS–(BUSINESS WIRE)–Cofactor Genomics today announced publication of its OncoPrism®-NSCLC clinical validation study in npj Precision Oncology, a peer-reviewed Nature Portfolio journal. The study represents the latest results from Cofactor’s multisite PREDAPT clinical trial and extends the clinical validation of the multidimensional RNA biomarker underlying OncoPrism-HNSCC—a clinically validated, Medicare-covered test for recurrent or metastatic head and neck squamous cell carcinoma—to a

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.